Pre-eclampsia is the most common complication that occurs during pregnancy. However, a simple blood test can help doctors to diagnose pre-eclampsia much faster and accurately. The findings of the study are published in the The Lancet journal.
A new study has found that a simple blood test can help make the diagnosis for a common and potentially fatal pregnancy complication.
Pre Eclampsia
In pre eclampsia a pregnant woman develops high blood pressure and proteinuria during pregnancy.
Advertisement
‘Measuring the concentration of placental growth factor (PlGF) in a woman's blood can help doctors to diagnose pre-eclampsia much faster and accurately.’
Read More..
Tweet it Now
Read More..
The team of scientists from King's College London found that by measuring the concentration of placental growth factor (PlGF) in a woman's blood, doctors were able to diagnose pre-eclampsia on average two days sooner. This was associated with significant improvements in outcomes for women without causing health problems for babies.
Lead author Professor Lucy Chappell, NIHR Research Professor in Obstetrics at King's College London said: "For the last hundred years, we have diagnosed pre-eclampsia through measuring blood pressure and checking for protein in a woman's urine. These are relatively imprecise and often quite subjective.
![Risk of Stroke Increased Significantly in Women With Pre-eclampsia]( "Risk of Stroke Increased Significantly in Women With Pre-eclampsia")
Infections, hypertension, bleeding disorders, and clot-forming conditions increase stroke risk during and after childbirth.
"We knew that monitoring PlGF was an accurate way to help detect the condition but were unsure whether making this tool available to clinicians would lead to better care for women. Now we know that it does."
Between June 2016, and October 2017, the team from King's enrolled 1,035 women with suspected pre-eclampsia to the study from 11 maternity units across the UK. Women were randomly assigned to two groups. One had their PlGF test results made available to their clinical team, the other did not.
PlGF testing was shown to reduce the average time to pre-eclampsia diagnosis from 4·1 days to 1·9 days and serious complications before birth (such as eclampsia, stroke, and maternal death) from 5 percent to 4 percent.
There was no change in the likelihood of complications for the baby, the age at which babies were delivered prematurely or whether they were admitted to a neonatal unit. It was important that this test did not cause more unnecessary cases of preterm birth for babies.
In response to the trial, NHS England has announced that they would be making the test more widely available across the NHS.
Professor Tony Young, national clinical lead for innovation at NHS England, said: "This innovative blood test, as set out in this new study, helps determine the risks of pre-eclampsia in pregnancy, enabling women to be directed to appropriate care or reduce unnecessary worry more quickly.
"The NHS, with partners in government, will be making this test more widely available across the NHS as part of our plans to ensure as many patients as possible can benefit from world-class health innovations."
Professor Chappell added: "The evidence shows that widespread PlGF testing could save lives and it is fantastic news that NHS England agree. Many tests have come into practice without robust assessment. This time, we have evaluated this new test and shown that it improves care and outcomes for pregnant women and their babies."
Pre-eclampsia is suspected in around ten percent of UK pregnancies, affecting approximately 80,000 women annually. If untreated, it can progress to cause complications in the woman, including damage to vital organs, fits and can be fatal for the woman and baby. Globally, 100 women die as a result of the condition every day.
Source: Eurekalert
Risk of Stroke Increased Significantly in Women With Pre-eclampsia
Infections, hypertension, bleeding disorders, and clot-forming conditions increase stroke risk during and after childbirth.
Advertisement
"We knew that monitoring PlGF was an accurate way to help detect the condition but were unsure whether making this tool available to clinicians would lead to better care for women. Now we know that it does."
Between June 2016, and October 2017, the team from King's enrolled 1,035 women with suspected pre-eclampsia to the study from 11 maternity units across the UK. Women were randomly assigned to two groups. One had their PlGF test results made available to their clinical team, the other did not.
PlGF testing was shown to reduce the average time to pre-eclampsia diagnosis from 4·1 days to 1·9 days and serious complications before birth (such as eclampsia, stroke, and maternal death) from 5 percent to 4 percent.
There was no change in the likelihood of complications for the baby, the age at which babies were delivered prematurely or whether they were admitted to a neonatal unit. It was important that this test did not cause more unnecessary cases of preterm birth for babies.
In response to the trial, NHS England has announced that they would be making the test more widely available across the NHS.
Professor Tony Young, national clinical lead for innovation at NHS England, said: "This innovative blood test, as set out in this new study, helps determine the risks of pre-eclampsia in pregnancy, enabling women to be directed to appropriate care or reduce unnecessary worry more quickly.
"The NHS, with partners in government, will be making this test more widely available across the NHS as part of our plans to ensure as many patients as possible can benefit from world-class health innovations."
Professor Chappell added: "The evidence shows that widespread PlGF testing could save lives and it is fantastic news that NHS England agree. Many tests have come into practice without robust assessment. This time, we have evaluated this new test and shown that it improves care and outcomes for pregnant women and their babies."
Pre-eclampsia is suspected in around ten percent of UK pregnancies, affecting approximately 80,000 women annually. If untreated, it can progress to cause complications in the woman, including damage to vital organs, fits and can be fatal for the woman and baby. Globally, 100 women die as a result of the condition every day.
Source: Eurekalert
New Pre-Eclampsia Test Helps Avoid Preterm Delivery, Assess Maternal Risk
The new pre-eclampsia test could help save lives of hundreds of babies by avoiding preterm delivery and also assess the immediate risk to mothers.
Advertisement
Pre-Eclampsia may Increase Risk of Heart Disease Later in LifeThe artery wall thickness of women with a history of pre-eclampsia was significantly greater than those with normotensive pregnancies. | Advertisement
|
Advertisement
Recommended Reading
Latest Women Health News
Experts suggest that getting regular mammograms at the age of 40 can help women prevent breast cancer.
The commonly used Fracture Risk Assessment Tool (FRAX) is not useful for shared clinical decision-making regarding osteoporosis screening in younger postmenopausal women.
Researchers hypothesized that adverse pregnancy outcomes (APO) are associated with younger age at first stroke, with a stronger relationship in those with >1 pregnancy with APO.
Women grapple with the risk of mental illnesses as immense challenge of constantly striving for perfection and balancing multiple roles takes a toll.
Irrespective of dietary preferences, lactating mothers maintain similar concentrations of nutrients in their breast milk, when comparing vegan and omnivorous diets.